Piramal Healthcare is currently trading at Rs. 444.10, up by 0.30 points or 0.07% from its previous closing of Rs. 443.80 on the BSE.
The scrip opened at Rs. 450.00 and has touched a high and low of Rs. 451.00 and Rs. 442.00 respectively. So far 4714 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 562.50 on 02-Apr-2012 and a 52 week low of Rs. 340.00 on 30-Nov-2011.
Last one week high and low of the scrip stood at Rs. 470.00 and Rs. 438.10 respectively. The current market cap of the company is Rs. 7663.53 crore.
The promoters holding in the company stood at 53.08% while Institutions and Non-Institutions held 25.97% and 20.95% respectively.
Piramal Imaging SA (Piramal), a newly formed subsidiary of Piramal Healthcare has received positive results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer’s disease. The study results will be featured as part of the Emerging Science Program on April 25, 2012 at the American Academy of Neurology’s 64th Annual Meeting in New Orleans.
The only way to definitively diagnose Alzheimer’s disease has been after death - at autopsy - through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain PET imaging with florbetaben to post-mortem analysis of the brain tissue.
Besides, Piramal has signed an agreement to acquire worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG through its newly created subsidiary - Piramal Imaging SA. Florbetaben is the lead compound in the portfolio.
Piramal Healthcare is one of the largest custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 6900.10 |
| Shriram Finance | 2885.50 |
| Aditya Birla Capital | 187.20 |
| SBI Cards AndPayment | 692.60 |
| Mah & Mah Finl. Serv | 266.05 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
